Dave Muoio

By Dave Muoio 03:59 pmNovember 6, 2019
Due to their increasingly personalized and convenient experiences with other sectors, consumers have high expectations when it comes to the services they’re receiving from the healthcare industry, according to a new global survey from Salesforce Research of nearly 6,000 consumers. Unfortunately, nearly half (47%) of those polled believe that the healthcare and life sciences are less focused on...
By Dave Muoio 11:20 amNovember 6, 2019
Boston-based PathAI, maker of artificial intelligence tools for pathology, has capped off its Series B funding round with a $15 million strategic investment from the Merck Global Health Innovation Fund and Bristol-Myers Squibb. This raise brings the startup’s full round to $75 million, and its total funding to just over $90 million. WHAT THEY DO PathAI’s platform employs convolutional neural...
By Dave Muoio 03:03 pmNovember 5, 2019
Friday marked the end of Dr. Ned Sharpless’ time as acting commissioner of the FDA, with President Donald Trump pointing to Dr. Stephen Hahn, currently the chief medical officer of MD Anderson Cancer Center, as his official appointment for the role on Friday. Assistant Secretary for health at HHS Dr. Brett Giroir will act as the agency’s new acting head. “With Dr. Sharpless at the helm, the FDA...
By Dave Muoio 02:41 pmNovember 5, 2019
Scanwell Health, maker of a smartphone-based platform for home urinary tract infection screening, has raised $3.5 million in seed funding. Founders Fund, Mayfield, DCM, Version One, Y Combinator and Liquid 2 Ventures all participated in the round. The startup paired this announcement with the reveal of a new partnership with telehealth service Lemonaid Health that will bring its UTI platform to...
By Dave Muoio 12:00 pmNovember 5, 2019
Type 1 diabetes management and CGM integration are now on the table for WellDoc’s BlueStar, a management platform well known for being the first mobile health product to secure reimbursement as a diabetes therapy. Thanks to a new FDA clearance, the company’s seventh, BlueStar will include integrated glucose level insights related to food, medication and activity that are based on the data from...
By Dave Muoio 02:26 pmNovember 4, 2019
The FDA has issued a class two device recall for Senseonics’ Eversense continuous glucose monitoring system. This posting follows a September notice from the company that alerted providers and distributors in the US that the sensors of certain devices may stop working prematurely. Senseonics identified a small number of Eversense Sensors that have prematurely stopped functioning due to inadequate...
By Dave Muoio 03:32 pmOctober 31, 2019
Apple's high on health. Apple CEO Tim Cook was pleased as punch with his company’s latest quarterly and yearly report, which he said on an investor’s call yesterday was Apple’s “highest revenue in a September quarter ever” at $64 billion. Thirty-three million dollars of this was in iPhone revenue — a 9% decline over last year that he felt was a significant step up from the 15% decline seen...
By Dave Muoio 01:48 pmOctober 31, 2019
Roughly two years after the fact, digital healthcare advertiser Outcome Health is finally closing the loop on its ad fraud scandal. Yesterday the Chicago-based company and the US Department of Justice announced a $70 million settlement alongside an admission that the company’s former executives and employees sold falsified advertising inventory from 2012 to 2017. “Outcome Health deceived its...
By Dave Muoio 04:06 pmOctober 30, 2019
Mirror, a fitness content streaming device that users can hang and use like a traditional full-length mirror, has raised $34 million more in a Series B-1 funding round headed by Point72 Ventures. Others now backing the startup include athletic apparel retailer lululemon, LionTree LLC and individual backers including Karlie Kloss, Kevin Huvane and Steve Lockshin. Prior investors Spark Capital and...
By Dave Muoio 11:47 amOctober 30, 2019
Pear Therapeutics has announced a new deal with Ironwood Pharmaceuticals that will explore the platform’s potential for patients with certain gastrointestinal (GI) conditions. “We are excited to be partnering with Ironwood on this initiative and believe there is a compelling clinical rationale for use of [prescription digital therapeutics] in treating GI diseases,” Dr. Corey McCann, president and...